INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 203 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $128,556 | -7.1% | 330,477 | +6.6% | 0.00% | – |
| Q2 2023 | $138,410 | -52.2% | 309,988 | -12.2% | 0.00% | – |
| Q1 2023 | $289,558 | -28.3% | 353,120 | +36.4% | 0.00% | – |
| Q4 2022 | $403,922 | -5.6% | 258,924 | +4.3% | 0.00% | – |
| Q3 2022 | $428,000 | -2.1% | 248,253 | -1.8% | 0.00% | – |
| Q2 2022 | $437,000 | -44.2% | 252,718 | +15.9% | 0.00% | – |
| Q1 2022 | $783,000 | +96.2% | 218,103 | +173.0% | 0.00% | – |
| Q4 2021 | $399,000 | -39.7% | 79,877 | -13.7% | 0.00% | – |
| Q3 2021 | $662,000 | -15.1% | 92,556 | +9.9% | 0.00% | – |
| Q2 2021 | $780,000 | +71.4% | 84,184 | +71.8% | 0.00% | – |
| Q1 2021 | $455,000 | +55.8% | 49,001 | +48.7% | 0.00% | – |
| Q4 2020 | $292,000 | -31.9% | 32,959 | -10.7% | 0.00% | – |
| Q3 2020 | $429,000 | -88.7% | 36,906 | -73.7% | 0.00% | -100.0% |
| Q2 2020 | $3,786,000 | +287.5% | 140,509 | +6.9% | 0.00% | – |
| Q1 2020 | $977,000 | +608.0% | 131,389 | +214.4% | 0.00% | – |
| Q4 2019 | $138,000 | +51.6% | 41,787 | -6.3% | 0.00% | – |
| Q3 2019 | $91,000 | -33.1% | 44,613 | -3.8% | 0.00% | – |
| Q2 2019 | $136,000 | -67.0% | 46,353 | -58.0% | 0.00% | – |
| Q1 2019 | $412,000 | +80.7% | 110,328 | +93.4% | 0.00% | – |
| Q4 2018 | $228,000 | -40.5% | 57,048 | -17.3% | 0.00% | – |
| Q3 2018 | $383,000 | +88.7% | 68,957 | +33.0% | 0.00% | – |
| Q2 2018 | $203,000 | +133.3% | 51,829 | +180.3% | 0.00% | – |
| Q1 2018 | $87,000 | +27.9% | 18,489 | +12.2% | 0.00% | – |
| Q4 2017 | $68,000 | -32.7% | 16,472 | +3.3% | 0.00% | – |
| Q3 2017 | $101,000 | -13.7% | 15,944 | +6.8% | 0.00% | – |
| Q2 2017 | $117,000 | -98.4% | 14,924 | -98.1% | 0.00% | -100.0% |
| Q3 2016 | $7,431,000 | +20.0% | 797,317 | +19.0% | 0.00% | +50.0% |
| Q2 2016 | $6,191,000 | +123720.0% | 670,030 | +110283.9% | 0.00% | – |
| Q2 2015 | $5,000 | -94.0% | 607 | -92.8% | 0.00% | – |
| Q3 2014 | $83,000 | -33.6% | 8,389 | -27.3% | 0.00% | – |
| Q2 2014 | $125,000 | – | 11,546 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |